REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Preparations Characterized By Special Physical Form > Tablets, Lozenges, Or Pills > Sustained Or Differential Release Type Sustained Or Differential Release TypeSustained Or Differential Release Type patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.07/26/07 - 20070172525 - Anti-diabetic combinations This invention a pharmaceutical composition comprising a DPP inhibitor and a slow release biguanide. The invention further discloses a method of administering a combination comprising a DPP inhibitor and a slow release biguanide to a mammal in need of thereof. ... 07/19/07 - 20070166378 - Oral ribavirin pharmaceutical compositions The invention relates to oral pharmaceutical compositions for the prevention and/or the treatment of viral diseases. This invention also addresses methods of prevention and/or treatment of these viral diseases, using these oral compositions. One of the main problems considered in the present invention is to enhance the efficiency of anti-viral ... 07/12/07 - 20070160668 - Prolonged release bioadhesive therapeutic systems The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. Said bioadhesive therapeutic system comprises quantities of natural proteins representing at least 50% ... 07/12/07 - 20070160667 - Controlled release formulation of divalproex sodium The present invention provides a controlled release dosage formulation comprising a) about 40% to about 80% of a valproic acid compound such as Divalproex Sodium and b) at least two, preferably hydrophilic, polymers each in an amount of less than about 20% of the dosage weight. ... 07/05/07 - 20070154548 - Controlled release metformin formulations Sustained release pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period after administration. ... 07/05/07 - 20070154546 - Sustained release pharmaceutical compositions The present invention relates to a pharmaceutical composition comprising a salt of quaternary ammonium of an acid drug in the form of a suspension or an emulsion, suitable for parenteral administration and providing a sustained release of the drug. In one preferred embodiment, the present invention is directed to a ... 06/28/07 - 20070148237 - Sustained-release formulation of zonisamide Pharmaceutical formulations comprise sustained-release zonisamide. Methods of preparing such pharmaceutical formulations involve intermixing zonisamide with a suitable excipient configured to control the dissolution profile of the zonisamide. Methods of treatment involve administering the pharmaceutical formulations to patients in need of such treatment. ... 06/21/07 - 20070141148 - Neramexane mr matrix tablet The invention provides novel oral modified release dosage forms of neramexane which are useful for the continuous therapy of patients suffering from diseases and conditions such as Alzheimer's dementia and neuropathic pain. The compositions have drug release profiles that are suitable for achieving steady state plasma concentrations of neramexane which ... 06/21/07 - 20070141146 - Novel compositions An oral dosage form that provides controlled release of an active pharmaceutical agent, 5 -[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (hereinafter ‘Compound A’) or a pharmaceutically acceptable salt or solvate thereof in different body environments, a process for the preparation of such an oral dosage form, and the use of such a dosage form ... 06/14/07 - 20070134328 - Oxymorphone controlled release formulations The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief. ... 06/14/07 - 20070134327 - Compositions and methods for improved efficacy of penicillin-type antibiotics Disclosed are once-a-day penicillin-type antibiotic products comprising at least one modified release dosage form comprising penicillin-type antibiotics and pharmaceutically acceptable carriers, which compositions provide T>MIC90 in the serum for at least 5 hours (preferably for at least five consecutive hours), within a 24-hour dosing interval, for a given bacterial pathogen's ... 06/14/07 - 20070134326 - Composition for releasing a weak base for an extended period of time An oral dosage form comprising a first composition and a second composition, each composition comprising a pharmaceutically acceptable weak base, especially Compound A or a pharmaceutically acceptable salt or solvate thereof, (‘the drug’) and a pharmaceutically acceptable carrier therefor, wherein the first and second compositions are arranged to release drug ... 06/07/07 - 20070128276 - Controlled release compositions comprising nimesulide A controlled release composition comprising nimesulide as an active agent formulated as a gastroretentive system, preferably as a solid oral dosage form is provided, wherein the residence time of the active agent is increased in the stomach, duodenum, jejunum or ileum. The present invention also provides process of preparing such ... 06/07/07 - 20070128275 - Trazodone composition for once a day administration The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 ... 05/31/07 - 20070122479 - Threo-dops controlled release formulation The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an extended or slow release component that maintains therapeutic concentration of threo-DOPS in the blood plasma over a prolonged time period. They can be further combined with an ... 05/31/07 - 20070122478 - Extended release composition containing tramadol The preparation provides, effective blood concentration for a period of about 24 hours with reduced peak concentrations. It is characterized that effective Tramadol levels appears within the first hours after administration, the time to maximal Tramadol content Tmax is at least 10 hours and the peak Tramadol concentration is less ... 05/31/07 - 20070122477 - Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency A controlled-release pharmaceutical formulation including cholecalciferol and/or ergocalciferol, a method of making the formulation, and a method of administering the formulation to treat 25-hydroxyvitamin D insufficiency or deficiency, are disclosed. The composition and method of administration preferably result in delayed release of the vitamin(s) in the ileum of the small ... 05/24/07 - 20070116763 - Sustained release oral preparations An object of the present invention is to provide a pharmaceutical preparation containing the drug as an active ingredient, which is capable of improving the QOL and the compliance of the patient who doses the drug while avoiding any excessive increase in the plasma level of the drug by means ... 05/17/07 - 20070110805 - Modified-release pharmaceutical compositions This invention is directed generally to modified-release pharmaceutical compositions, and, more particularly, to modified-release anesthetic- or analgesic-comprising pharmaceutical compositions that are bioadherent to a vaginal cavity surface, vulva surface, or skin. This invention also is directed generally to methods for preparing such compositions, methods of treatment using such compositions, uses ... 05/17/07 - 20070110804 - Drug polymer complexes This invention relates to polymeric complexes of drugs to be employed as (or in) sustained release-formulations comprising a cationic active agent, and a polyanionic water soluble complexing polymer of sufficient molecular weight that it forms a gel when mixed with said active agent. The invention also relates to the manufacture ... 05/10/07 - 20070104788 - Once-daily administration of central nervous system drugs Delayed onset chronotherapeutic formulations of central nervous system (CNS) drugs are disclosed. The formulations comprise at least one CNS drug or pharmaceutically acceptable salt thereof that exhibits an in vivo elimination half-life of less than about 8 hours, wherein the formulation exhibits at least one in vivo parameter, at steady ... 05/10/07 - 20070104787 - Carboxyalkyl cellulose esters for sustained delivery of pharmaceutically active substances wherein: R1-R6 are each independently selected from —OH, —OC(O)(alkyl), and —O(CH2)xC(O)OH, and pharmaceutically acceptable salts thereof, wherein x ranges from 1-3, a degree of substitution per anhydroglucose of —OH ranges from 0.1 to 0.7, a degree of substitution per anhydroglucose of —C(O)(alkyl) ranges from 0.1 to 2.7, and a degree ... 05/10/07 - 20070104786 - Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate The present invention provides a gastric retention dosage form for immediate or uncontrolled release of a vitamin D derivative that stimulates calcium absorption from the intestine, like calcitriol, alphacalcidol and calcifediol, combined with delayed release of a bis-phosphonate calcium resorption inhibitor such as alendronic acid and its pharmaceutically acceptable salts ... 05/03/07 - 20070098795 - Pharmaceutical formulation A solid, oral controlled release pharmaceutical dosage form has a water-soluble active ingredient dispersed in a matrix and releases the active ingredient at such a rate upon administration that the median tmax is 2.5 to 6 hours and the ratio of mean Cmax to mean plasma level of the active ... 05/03/07 - 20070098794 - Oxymorphone controlled release formulations The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief. ... 05/03/07 - 20070098793 - Oxymorphone controlled release formulations The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief. ... 05/03/07 - 20070098792 - Oxymorphone controlled release formulations The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief. ... 05/03/07 - 20070098791 - Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate ... 05/03/07 - 20070098790 - Nutritional supplement for the enhancement of the health of the liver Compositions, systems, and methods of enhancing the health of the liver are disclosed. The synergistic effect of N-acetylcysteine, glutathione, vitamin C and vitamin E is to counteract the toxic effects of analgesics such as acetaminophen on the liver. Also disclosed is an enteric coating material which may be used with ... 04/26/07 - 20070092567 - Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin A controlled Release Pharmaceutical composition comprising an effective amount of Pravastatin and Fenofibrate, characterised in that the difference, in absolute value, between the times of maximal concentration (Tmax) of Pravastatin and Fenofibric acid is not less than 1.5 hours upon administration with food to humans. ... 04/26/07 - 20070092566 - Oral sustained-release tablet An oral sustained-release tablet is provided, which does not cause initial rapid increases in the bloodlevels of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide (KRP-197) and can maintain constant the blood levels. (Solving means) An oral sustained-release tablet comprises a pharmaceutical composition and a gel-forming material, the pharmaceutical composition containing KRP-197 as an active ingredient. ... 04/19/07 - 20070087055 - Directly compressible extended release alprazolam formulation A directly compressible extended release pharmaceutical dosage form comprising alprazolam and at least two high viscosity polymers, wherein said first high viscosity polymer and said second high viscosity polymer are present in a ratio from about 4:1 to about 2:1. ... 04/12/07 - 20070082051 - Modified release formulations of antihypertensive drugs Modified or extended release formulations containing propanolol compounds and associated methods are disclosed and described. In some aspects, such formulations may be substantially bioequivalent to known FDA approved propanolol formulations such as INDERAL LA®. ... 04/12/07 - 20070082050 - Modified release formulations of antihypertensive drugs Modified or extended release formulations containing propanolol compounds and associated methods are disclosed and described. In some aspects, such formulations may be substantially bioequivalent to known FDA approved propanolol formulations such as INDERAL LA®. ... 04/12/07 - 20070082049 - Extended release venlafaxine tablet formulation An extended release formulation for administration of venlafaxine in an oral tablet dosage form. The formulation preferably features a core, over which an outer coating is layered. The core preferably contains venlafaxine, a filler, and a water soluble cellulosic polymer, optionally and more preferably with a water insoluble cellulosic polymer. ... 04/05/07 - 20070077298 - Soy-based thermosensitive hydrogels for controlled release systems Biopolymeric hydrogel precursors are prepared by means of a ring-opening polymerization of epoxidized vegetable oils, followed by chemical hydrolysis. The recovered hydrogels having properties similar to Pluronic® type surfactants would have a plurality of end-use applications, including use as food additives and pharmaceutical ingredients. This invention provides the potential for ... 03/29/07 - 20070071819 - Multiple unit modified release compositions of carbamazepine and process for their preparation The present invention relates to multiple-unit modified release carbamazepine compositions for oral administration which include: (i) at least one extended release unit, and (ii) at least one enteric release unit. Also provided are processes for the preparation of multiple-unit modified release compositions of carbamazepine. ... 03/22/07 - 20070065511 - Controlled delivery creatine formulations and method of using the same Controlled delivery formulations of creatine and a method of using the same are disclosed. Creatine is combined with an encapsulation/delivery agent and/or excipient, which act in such a way as to provide controlled delivery of creatine. This delivery profile substantially increases the period of time over which levels of creatine ... 03/22/07 - 20070065510 - Novel controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum The present invention provides a controlled release device for sustained or pulsatile delivery of pharmaceutically active substances for a predetermined period of time. This invention further provides such device in which sustained or pulsatile delivery is obtained by the unique blend and intimate mixture of pharmaceutically active substance with a ... 03/15/07 - 20070059366 - Sustained-release formulation and uses thereof The present invention provides sustained-release formulations useful and methods for using the same. ... 03/15/07 - 20070059365 - Novel formulation of ropinirole The present invention relates to novel formulations of ropinirole for oral administration and to their use in the treatment of diseases which can prevent or disturb sleep, particularly Restless Legs Syndrome (RLS). ... 03/15/07 - 20070059364 - Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity The present invention relates to an active substance combination comprising at least one compound with neuropeptide Y-receptor affinity and at least one compound with 5-HT6 receptor affinity, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament. ... 03/15/07 - 20070059363 - Method of preparing mixed formulation of sustained release microspheres by continuous one-step process Disclosed is a method for preparing a mixed formulation of sustained release microspheres with various compositions by a continuous one-step process. The present method is characterized by preparing the mixed formulation of sustained release microspheres with different compositions by a continuous one-step process by continuously introducing the mixed fluids into ... 03/08/07 - 20070053980 - Extended release tiagabine formulations with reduced side-effects Extended release tiagabine formulations that demonstrate fewer side-effects when administered to a patient. ... 03/08/07 - 20070053979 - Controlled release formulation of erythromycin derivatives The present invention is directed to a controlled release formulation in tablet form comprising a pharmaceutically effective amount of an erythromycin derivative and a lubricating effective amount of a lubricant in the absence of material selected from the group consisting of alginic acid or salts thereof or hydrophilic sustained release ... 03/01/07 - 20070048377 - Drug compositions containing controlled release hypromellose matrices This invention is directed to a controlled release formulation for an oral dosage form that is formulated into a swellable, hydrophilic matrix. The controlled release formulation contains a mixture of hypromellose and polyvinyl acetate phthalate and allows pharmaceutically active ingredients combined therewith to be released in a controlled release manner. ... 03/01/07 - 20070048376 - Sustained release formulations of nalbuphine Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided. ... 02/22/07 - 20070042042 - Metformin tablet with sustained release and method for preparing the same The present invention relates to a metformin tablet with sustained release and a method for preparing the same, more particularly to an improved metformin tablet with sustained release prepared by manufacturing a composition comprising metformin, which is an active ingredient for treatment of insulin-independent diabetes, and a matrix capable of ... 02/22/07 - 20070042041 - Drug-surfactant complexes for sustained release The invention involves sustained-release pharmaceutical compositions containing a water-soluble ionic small molecule pharmaceutical agent complexed with an oppositely charged surfactant, particularly a natural bile surfactant. The complexes are sustained-release ionic complexes. The complexes release the ionic pharmaceutical agents into aqueous solution slowly and with zero-order kinetics. Thus, they can be ... 02/22/07 - 20070042040 - Methods and compositions using gonadotropin hormone releasing hormone The present invention relates to compositions comprising two sustained release formulations, the first being capable of releasing a gonadotropin releasing hormone composition and the second an estrogenic composition. The compositions of the invention can be employed for an improved androgen deprivation therapy of prostate cancer, in which therapy loss of ... 02/15/07 - 20070036855 - Soft polylactides Biodegradable polymeric compositions that are liquids or pastes at temperatures below 37° C. are described. Immersion of the compositions in aqueous medium, such as body fluids, increases the viscosity of the composition resulting in the formation of a semisolid material. The polymeric material is a hydroxyalkanoic acid polyester derived from ... 02/08/07 - 20070031493 - Pharmaceutical compositions The present invention relates to pharmaceutical compositions for sustained release comprising a water soluble salt of the HMG-CoA reductase inhibitor fluvastatin as active ingredient, said composition being selected from the group comprising matrix formulations, diffusion-controlled membrane coated formulations; and combinations thereof. ... 02/08/07 - 20070031492 - Remote controlled synthesis system A synthesis system and a method for implementing the synthesis system is provided and includes a first synthesis portion and a second synthesis portion. The first synthesis portion includes at least one input device, at least one material collection device, at least one container and at least one configurable flow ... 02/08/07 - 20070031491 - Bioadhesive progressive hydration tablets A bioadhesive controlled, extended release progressive hydration composition wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may ... 02/01/07 - 20070026067 - Liquid formulations for controlled delivery of benzisoxazole derivatives Disclosed are dosage forms including a controlled release dosing structure; and a liquid formulation contained within the controlled release dosing structure; wherein the liquid formulation comprises a benzisoxazole derivative and a liquid carrier. Also disclosed are methods of making and using such dosage forms. ... 02/01/07 - 20070026066 - Oral pharmaceutical delivery system with improved sustained release A solid orally ingested delivery system having at least one lipid, dry particles including at least one pharmaceutical, and at least one filler, where the dry particles are continuously coated by the lipid and form a homogeneous suspension with the lipid, and at least part of the pharmaceutical is microencapsulated ... 02/01/07 - 20070026065 - Solid, modified-release pharmaceutical dosage forms which can be administered orally The present invention relates to solid, modified-release pharmaceutical dosage forms which can be administered orally and comprise 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide, and process for their production, their use as medicaments, their use for the prophylaxis, secondary prophylaxis and/or treatment of disorders, and their use for producing a medicament for the prophylaxis, secondary prophylaxis ... 01/25/07 - 20070020333 - Controlled release of hypnotic agents The application relates to the controlled release of a hypnotic agent with extended release profiles. The pharmaceutical composition and processes for manufacturing, and methods of using the controlled release formulation are provided. ... 01/18/07 - 20070014859 - Highly bioavailable oral delayed release dosage forms of o-desmethylvenlafaxine succinate An oral, highly bioavailable unit dosage form of O-desmethylvenlafaxine succinate (DVS) having a delayed release of at least about one hour and a sustained release over multiple hours to provide a total release of greater than about 85% within about 12 to about 14 hours is described. In one embodiment, ... 01/11/07 - 20070009598 - Sustained-release microgranules containging gingko biloba extract and the process for manufacturing these The subject of the present invention is a new stable herbal drug formulation in the form of sustained-release microgranules containing Gingko Biloba extract as well as the process for preparing it. ... 01/11/07 - 20070009597 - Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity The present invention relates to an active substance combination comprising at least one compound with neuropeptide Y-receptor affinity, preferably neuropeptide Y5-receptor affinity, and at least one compound with 5-HT6 receptor affinity, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of ... 01/11/07 - 20070009596 - Controlled drug release composition resistant to in vivo mechanic stress The controlled release units of the present invention are capable of maintaining the drug/s sustained release properties along the gastro-intestinal tract without losing their mechanical resistance induced by the in vivo peristalsis. The formulations object of the present invention are based on a matrix consisting in a glyceryl ester in ... 01/04/07 - 20070003618 - Sustained-release tramadol formulations with 24-hour efficacy A sustained-release tramadol formulation oral administration is provided which, upon initial administration of one dose, provides an analgesic effect within 2 hours, which analgesic effect continues for at least 24 hours after administration ... 01/04/07 - 20070003617 - Morphine controlled release system A composition for controlled release of an opioid from a pharmaceutical composition, the method comprises controlling the release of at least one opioid into an aqueous medium by erosion of at least one surface of a pharmaceutical composition comprising I) a matrix composition comprising a) polymer or a mixture of ... 12/28/06 - 20060292222 - Drug delivery device having zero or near zero-order release kinetics The present invention is directed to an improved sustained release drug delivery device comprising a drug core, a cup, and a prefabricated crystalline or semi-crystalline polymeric permeable plug. ... 12/28/06 - 20060292221 - Timed-release compression-coated solid composition for oral administration The present invention was completed based on these discoveries and relates to in a hydrogel-forming compression-coated solid pharmaceutical preparation comprising a core tablet containing drug and outer layer made from hydrogel-forming polymer substance and hydrophilic base, the improvement, a timed-release compression-coated solid composition for oral administration, said composition comprising (1) ... 12/07/06 - 20060275366 - Controlled-release formulation Controlled-release dosage formulations including at least one compound of Formulae I to XXVI herein and a controlled-release carrier and methods of treatment using the same are provided. ... 11/30/06 - 20060269604 - Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level Patients are treated with 24-hour oral sustained release opioid formulations which, upon administrations, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause ... 11/30/06 - 20060269603 - Controlled release tramadol formulations A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient. ... 11/30/06 - 20060269602 - Method of modifying the release profile of sustained release compositions The present invention relates to a method for the sustained release in vivo of a biologically active agent comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having the biologically active agent incorporated therein, and a bisphosphonate wherein ... 11/30/06 - 20060269601 - Oral modified release formulations containing 8-prenylnaringenin for continuous estrogen support This invention is directed to an oral modified release formulation of the phytoestrogen 8-prenylnaringenin and methods for the treatment of symptoms of estrogen deficiency. ... 11/23/06 - 20060263428 - Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics Methods for treating hyperlipidemia with intermediate release nicotinic acid formulations having unique biopharmaceutical characteristics, without causing drug-induced hepatotoxicity to a level which would require discontinuation of the therapy, whereby a majority of the nicotinic acid is release and metabolized in the individual within about 5 to about 9 hours. The ... 11/23/06 - 20060263427 - Quinine formulations Disclosed herein are controlled-release quinine formulations and methods of preparing the same. Also disclosed are methods of preventing or treating malaria, leg cramps, or babesiosis by administering the controlled-release quinine formulations. The controlled-release quinine formulations may help to reduce or eliminate adverse side effects typically associated with the dosing of ... 11/23/06 - 20060263426 - Oral administration form for pyridin-2-ylmethysulfinyl-1h-bezimidazoles The invention relates to an oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles and their salts, which comprises the active compound together with tablet disintegrants and is provided with a film coating customary per se for sustained-release compositions. ... 11/16/06 - 20060257481 - Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy The invention relates to improved materials and methods for therapy to inhibit production of leukotrienes, and all therapeutic applications thereof. ... 11/16/06 - 20060257480 - Pharmaceutical formulations of amyloid inhibiting compounds Therapeutic formulations and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Therapeutic formulations and methods for preventing or treating amyloidosis and/or amyloid-related disease are also described. ... 11/16/06 - 20060257479 - Long-acting molecules in sustained release formulations Sustained release formulations comprising molecules modified so as to have a reduced clearance is provided. ... 11/09/06 - 20060251721 - Controlled release formulations of opioid and nonopioid analgesics Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective ... 11/09/06 - 20060251720 - Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins The present invention relates to a localized controlled absorption formulation of a statin in which rapid release of the active ingredient preferentially occurs in the lower gastrointestinal tract including the colon. The formulation provides significantly higher blood level concentration and bioavailability of the active ingredient in the body of a ... 11/09/06 - 20060251719 - Sustained-release hydrogel preparation A sustained-release preparation is provided which comprises a drug and a bioabsorbable polymer hydrogel, wherein a concentration gradient of the drug is formed in the hydrogel. Also disclosed is a method of sustained release of a drug in vivo using the sustained-release preparation of the invention. The directionality of the ... 11/02/06 - 20060246133 - Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same This invention relates to sustained release pharmaceutical compositions comprising liothyronine, or a salt or derivative thereof. Additionally, the present invention is directed to methods of manufacture and methods of using the pharmaceutical compositions of the present invention. ... 11/02/06 - 20060246132 - Sustained release formulations of venlafaxine The present invention relates to sustained release tablet formulations of venlafaxine. Kollidon SR proved to be an excellent sustained release agent for venlafaxine, that is an extremely soluble drug. ... 10/26/06 - 20060240104 - Controlled or sustained-release formulation A formulation comprising: a co-polyester comprising (a) the reaction product of a polycondensation polyester and (b) glycolide; wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and ethylene glycol, and the co-polyester comprises about 40% by weight of the polycondensation polyester based on the ... 10/19/06 - 20060233878 - Extended release formulation of beta-lactam antibiotics A pharmaceutical composition for controlled drug delivery comprising a β-lactam antibiotic or its pharmaceutically acceptable hydrates, salts or esters, and one or more carbomers. The above β-lactam antibiotics formulation avoids the limitations of known β-lactam controlled release form which are found to be either complex and/or cost-extensive to obtain requiring ... 10/19/06 - 20060233877 - Betaine compositions The invention refers to the pharmaceutical combination including at least: a first compound selected among the group consisting of acetylsalicylic acid, salicylic acid, pharmaceutical derivatives thereof, and a second compound selected from the group consisting of lipidic betaines, betaines lipids, betaines of Formula (CH3)3N+(CH2)nCOO− with n an integer from 1 ... 10/12/06 - 20060228413 - Controlled release venlafaxine formulations In certain embodiments, the present invention is directed to a controlled release oral dosage form comprising: a therapeutically effective amount of venlafaxine or a pharmaceutically acceptable salt thereof and a controlled release material; wherein the amount of venlafaxine or pharmaceutically acceptable salt thereof released at 1 hour in 900 mL ... 10/05/06 - 20060222708 - Wafer comprising steroid hormones The invention relates to a pharmaceutical composition in the form of a system in film form for transmucosal administration of steroid hormones. An administration system for steroid hormones which dissolves in the mouth and which releases with a high bioavailability is disclosed. The administration system in film form dissolves in ... 09/21/06 - 20060210630 - Controlled release compositions of gamma-hydroxybutyrate The present invention is directed to oral pulse-release pharmaceutical dosage form containing an immediate release component of gamma-hydroxybutyric acid, and one or more delayed/controlled release components of gamma-hydroxybutyric acid. ... 09/21/06 - 20060210629 - Zinc-containing sustained-release composition, its preparation, and method for producing the same With a simple and high-yield production method, a zinc-containing sustained-release composition capable of stabilizing a physiologically active protein or peptide, typically G-CSF by precipitation and retaining drug efficacy for several days in a living body owing to its sustained releasability is provided. Concretely, a zinc-containing sustained-release composition produced by forming ... 09/14/06 - 20060204574 - Sustained-release oral administration preparation of phenylalanine derivatives The present invention provides sustained-release oral administration preparations containing the phenylalanine compound of the formula (1) wherein A represent the formula (2) and the like; B represents an alkoxy group and the like; E represents a hydrogen atom and the like; D represents a substituted phenyl group and the like; ... 09/14/06 - 20060204573 - Control release formulation containing a hydrophobic material as the sustained release agent The present invention is directed to a sustained release pharmaceutical composition in oral dosage form consisting essentially of a pharmaceutically effective amount of a medicament and a hydrophobic material in the absence of a lactose or hydrophobic carbohydrate polymer, said medicament being present in an amount greater than about 25% ... 09/07/06 - 20060198888 - Tolperisone-containing pharmaceutical preparation with controllable active-substance release for oral administration The invention relates to a tolperisone-containing pharmaceutical preparation with controllable active-substance release for oral administration, characterised in that the active substance tolperisone and/or a pharmaceutical salt thereof is embedded in a pharmaceutically compatible material. By selecting the pharmaceutically compatible materials in the preparation and accordingly in the coating of a ... 09/07/06 - 20060198887 - Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least one water swelling polymer other than pregelatinized starch. ... 09/07/06 - 20060198886 - Medicament having coated methenamine combined with acidifier A solid pharmaceutical medicament has a coated methenamine compound in combination with an urinary acidifier. ... 08/31/06 - 20060193913 - 5-(4-(2-n-methyl-n-(2-pyridyl)amido)ethoxy)benzyl) thiazolidine-2,4-dione and pharmaceutical compositions comprising the same A compound, 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (‘Compound (I)’), or a pharmaceutically acceptable form thereof, in particulate form wherein the median value of the volume mean diameter of the particles is within the range 500 nm to 5 micrometres and medicinal uses thereof. ... 08/31/06 - 20060193912 - Controlled release o-desmethylvenlafaxine formulations In certain embodiments, the present invention is directed to a controlled release oral dosage form comprising a therapeutically effective amount of O-desmethylvenlafaxine or a pharmaceutically acceptable salt thereof and a controlled release material; wherein the amount of O-desmethylvenlafaxine or pharmaceutically acceptable salt thereof released at 1 hour in 900 mL ... 08/31/06 - 20060193911 - Controlled release venlafaxine formulations In certain embodiments, the present invention is directed to a controlled release oral solid dosage form comprising a matrix comprising a therapeutically effective amount of venlafaxine, an active metabolite of venlafaxine, or a pharmaceutically acceptable salt thereof, dispersed in a cross-linked gelling agent, the matrix providing a controlled release of ... 08/24/06 - 20060188575 - Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators A method is provided for treatment of non-painful bladder disorders, particularly non-painful overactive bladder without loss of urine. The method comprises administration of an α2δ subunit calcium channel modulator, including gabapentin, pregabalin, GABA analogs, fused bicyclic or tricyclic amino acid analogs of gabapentin, amino acid compounds, and other compounds that ... 08/24/06 - 20060188574 - Controlled release lipoic acid A controlled release formulation of lipoic acid is disclosed. The lipoic acid is combined with excipient materials in such a way that those materials provide for gradual release of the lipoic acid in a manner which makes it possible to substantially increase the period of time over which therapeutic levels ... 08/24/06 - 20060188573 - Composite materials and particles A method or concept for producing a composite material having at least an amphifilic (i.e., surface-active) and polymer component, and the composite material formed thereby, includes providing a mixture of at least one each of polymer and amphifilic compound in a volatile solvent or solvent mixture and providing a phase ... 08/24/06 - 20060188572 - Controlled release of s-methoprene and other active ingredients with activated carbon An effective controlled release pest control composition can use activated carbon as the sole release agent. Liquid pesticide is adsorbed into the interior mesopore and macropore space of the activated carbon. Upon contact with water, the pesticide is slowly displaced from the carbon into the environment for appropriate control. The ... 08/17/06 - 20060182805 - Dosage form and method for sustained release of substituted pyrazine compound The invention is directed to a dosage form and method for administering a therapeutic agent in a sustained release manner to provide an intended therapeutic effect while minimizing the side effects associated with the therapeutic agent. The therapeutic agent is selected from a group of substituted pyrazine compounds and may ... 08/17/06 - 20060182804 - Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods The present invention also relates to carvedilol free base, salts, anhydrous forms, or solvates thereof, corresponding pharmaceutical compositions or controlled release formulations, and methods delivery of carvedilol forms to the lower gastrointestingal tract or methods to treat cardiovascular diseases, which may include, but are not limited to hypertension, congestive heart ... 08/17/06 - 20060182803 - Oral sustained-release pharmaceutical composition of indapamide, production and use thereof The present invention relates to an oral sustained-release pharmaceutical composition of indapamide and a process for producing the foregoing pharmaceutical composition. The pharmaceutical composition comprises indapamide in the amount 0.2% to 4% (w/w) of the composition, a hydrophilic polymer in the amount 10% to 30% (w/w) of the composition, a ... 08/10/06 - 20060177507 - Controlled release device containing lercanidipine The present invention provides a simple and improved osmotic device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use. One or both of the passageways ... 08/10/06 - 20060177506 - Release control compositions wherein n is an integer of 1 to 3, and Ar is an aromatic ring which may be substituted, or a salt thereof, and a hydrophilic polymer, or a controlled release composition for oral administration, wherein a core containing the physiologically active substance is coated with a coating layer containing ... 08/03/06 - 20060172006 - Sustained-release tramadol formulations with 24-hour clinical efficacy There is disclosed a once daily oral pharmaceutical compositon for controlled release of tramadol or a salt thereof, wherein the composition, when ingested orally, provides a clinical effect over 24 hours which is a least as good as the clinical effect over 24 hours of two doses of a twice ... 07/27/06 - 20060165792 - Controlled release oxycodone compositions A method for substantially reducing the range in. daily dosages reguired to control pain-in-approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean ... 07/27/06 - 20060165791 - Controlled release oxycodone compositions A method for substantially reducing the range in daily dosages required to control pain in approximately. 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation ... 07/27/06 - 20060165790 - Multiparticulates Multipartulates of oxycodone can be made by extrusion of a blend which suitably contains (a) oxycodone, (b) water-insoluble ammonium methacrylate copolymer, (c) plasticiser, (d) lubricant and (e) water permeability modifier. ... 07/27/06 - 20060165789 - Lercanidipine modified release compositions Pursuant to the present invention, it has been found that a modified release composition containing the low permeability and poor solubility drug, lercanidipine, may be prepared which provides for therapeutically effective plasma concentrations of lercanidipine for a period of about 20 to about 25 hours. The modified release composition of ... 07/27/06 - 20060165788 - Lercanidipine ph dependent pulsatile release compositions Pursuant to the present invention it has been found that a modified release composition containing the low solubility and permeability drug, lercanidipine may be prepared that provides for therapeutically effective plasma concentrations of lercanidipine for 24 hours. The modified release composition of the present invention release pulses of lercanidipine based ... 07/27/06 - 20060165787 - Ceramic structures for controlled release of drugs The present invention provides compositions for controlled drug delivery, dosage forms, and processes for producing dosage forms. In a composition aspect of the present invention, a composition including a drug and a ceramic structure is provided. The ceramic structure has either a hollow portion wherein the drug is included in ... 07/27/06 - 20060165786 - Methods for treating circadian rhythm phase disturbances A method for treating circadian rhythm phase disorders is described. The invention provides methods to specifically advance or delay the phase of certain circadian rhythms in humans. The disclosed methods relate to the administration of melatonin at times determined with relation to the time of dim light endogenous melatonin onset. ... 07/20/06 - 20060159754 - Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent The present invention is directed to solid, sustained-release, oral dosage form pharmaceutical compositions which contain therapeutic amounts of a pharmaceutically active agent, hydroxypropyl methyl cellulose and a non-ionic, hydrophilic polymer selected from the group consisting of hydroxyethyl cellulose having a number average molecular weight ranging from 90,000 to 1,300,000, hydroxypropyl ... 07/20/06 - 20060159753 - Matrix type sustained-release preparation containing basic drug or salt thereof A matrix type sustained-release preparation and a manufacturing method therefor are provided wherein dissolution with low pH dependence of a basic drug or a salt thereof at the early stage of dissolution can be ensured in a dissolution test, and wherein as the dissolution test proceeds, a ratio of a ... 07/20/06 - 20060159752 - Extended release matrix tablets The present invention relates to extended release matrix tablets for oral administration that include a cationic polymer, a water-swellable polymer, and an alginic acid derivative to cause the release rate of the active ingredient of the tablets to be independent of pH and gastric residence time. The active pharmaceutical ingredient ... 07/20/06 - 20060159751 - Controlled release pharmaceutical compositions of carbidopa and levodopa The present invention relates to controlled release pharmaceutical compositions of carbidopa and levodopa that include a combination of different molecular weight cellulose ethers and in particular, hydroxypropyl cellulose ether. ... 07/13/06 - 20060153914 - Chronotherapeutic diltiazem formulations and the administration thereof A controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg or more (as desired) of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form ... 07/06/06 - 20060147528 - Extended release, multiple unit dosage forms of phenytoin sodium and processes for their preparation The present invention relates to oral extended release, multiple unit dosage forms of phenytoin sodium in which individual units comprising phenytoin sodium are coated with one or more film forming polymers. The individual units include between greater than 75% w/w and about 90% w/w of phenytoin sodium. ... 07/06/06 - 20060147527 - Controlled release preparations comprising tramadol and topiramate This invention relates to an oral pharmaceutical preparation, suitable for dosing every 24 hours, comprising a substrate, which substrate comprises a pharmaceutically effective amount of tramadol or a salt thereof and a pharmaceutically effective amount of topiramate and wherein said substrate may be coated with a controlled release coating; said ... 07/06/06 - 20060147526 - Pharmaceutical formulations comprising ß-2 adrenoreceptor agonists and xanthines A pharmaceutical formulation comprising (i) a sustained release layer comprising at least one xanthine, and (ii) an immediate release layer comprising at least one β-2 adrenoreceptor agonist selected from the group consisting of long acting and short acting β-2 adrenoreceptor agonists. ... 06/29/06 - 20060141036 - Hmg-coa reductase inhibitor extended release formulation Controlled release oral solid dosage form for the reduction of serum cholesterol levels in humans include a drug comprising an alkyl ester of hydroxy substituted naphthalenes (e.g., lovastatin) and a controlled release carrier, such that the dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug ... 06/29/06 - 20060141035 - Hmg-coa reductase inhibitor extended release formulation Controlled release oral solid dosage form for the reduction of serum cholesterol levels in humans include a drug comprising an alkyl ester of hydroxy substituted naphthalenes (e.g., lovastatin) and a controlled release carrier, such that the dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug ... 06/29/06 - 20060141034 - Gaba analog prodrug sustained release oral dosage forms Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective. ... 06/29/06 - 20060141033 - P-glycoprotein inhibitor comprising octilonium bromide as an effective ingredient The present invention relates to a new use of octylonium bromide as p-glycoprotein inhibitor to increase cellular uptake of drugs. More particularly, the present invention provides octylonium bromide as a p-glycoprotein inhibitor to increase cellular uptake of drugs such as anticancer drugs by taking octylonium bromide simultaneously with or proceding ... 06/22/06 - 20060134208 - Controlled release and taste masking oral pharmaceutical composition Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution ... 06/22/06 - 20060134207 - Dosage form containing diphenhydramine and another drug A pharmaceutical dosage form which comprises diphenhydramine and/or a pharmaceutically acceptable salt thereof and at least one second drug. The dosage form provides a plasma concentration within the therapeutic range of the at least one second drug over a period which is coextensive with a substantial part of the period ... 06/22/06 - 20060134206 - Oral compositions for treatment of diseases This invention describes the use of pharmaceutical compositions, which comprise three components of which at least one is a slow release therapeutic agent. Such useful compositions are applicable for the treatment of humans suffering from diabetic, hypertensive, cardiovascular, hyperlipidemic conditions and their associated disorders thereof. Combination therapy has the advantages ... 06/15/06 - 20060127476 - Tranexamic acid formulations with reduced adverse effects Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release ... 06/08/06 - 20060121113 - Pharmaceutical composition containing 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol with delayed active ingredient release Pharmaceutical compositions with delayed release which contains 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol or a pharmaceutically acceptable salt thereof in a matrix with delayed active ingredient release, wherein the matrix contains 1 to 80 wt. % of one or more hydrophilic or hydrophobic polymers as pharmaceutically acceptable matrix formers and exhibits the following in vitro ... 06/08/06 - 20060121112 - Topiramate pharmaceutical composition A once daily controlled-release pharmaceutical formulation which contains therapeutic amounts of topiramate and which is capable of being administered to specific regions along the gastrointestinal tract used to treat various types of conditions, for example, partial seizures with or without secondarily generalized seizures, primary generalized tonic-clonic seizures, seizures associated with ... 05/25/06 - 20060110455 - Antiviral product, use and formulation thereof An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more ... 05/25/06 - 20060110454 - Extended release formulation of pramipexole dihydrochloride An extended release composition of Pramipexole or a pharmaceutical acceptable salt thereof, wherein the active agent is coated on a non pareil inert core, the drug loaded core is further coated with a polymeric layer which enables the release of the active agent over an extended period and optionally the ... 05/18/06 - 20060105037 - Sustained release pharmaceutical preparations and methods for producing the same An extended release tablet comprising a core including albuterol sulfate and extended release agent; and an extended release coating on the core to provide for sustained release of the albuterol sulfate. ... 05/18/06 - 20060105036 - Threo-dops controlled release formulation The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an extended or slow release component that maintains therapeutic concentration of threo-DOPS in the blood plasma over a prolonged time period. They can be further combined with an ... 05/11/06 - 20060099255 - Controlled release oxycodone compositions A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation ... 05/11/06 - 20060099254 - Sustained release drug delivery system and method The present invention relates to a pharmaceutical delivery system comprising a gel-like structure that comprises at least one water-soluble polymer, such as, for example, povidone or hydroxypropyl cellulose, and at least one fatty acid, such as, for example, stearic acid or lauric acid. The invention further relates to a sustained ... 05/04/06 - 20060093671 - Controlled release galantamine composition The present invention is concerned with controlled release compositions for oral administration comprising galantamine; and with processes of preparing such controlled release compositions. ... 05/04/06 - 20060093670 - Sustained-release composition process for producing the same and preparation thereof The present invention provides a sustained-release composition by which a sustained-release effect can be obtained for a long time when injecting microparticles of the composition in an amount that can be subcutaneously or intramuscularly injected to a human with ease and without pain. The composition comprises porous hydroxyapatite microparticles having ... 04/27/06 - 20060088595 - Dispersant for sustained release preparations The present invention provides a bilayer dispersing agent for a sustained-release preparation, which contains a non water-soluble solvent and an aqueous solvent, and a sustained-release preparation wherein a microcapsule containing a physiologically active substance is dispersed in the aforementioned dispersing agent. When this preparation is subcutaneously administered, the initial release ... 03/30/06 - 20060068009 - Modified release ibuprofen dosage form The present invention is a solid dosage form for oral administration of ibuprofen comprising a modified release formulation of ibuprofen which provides an immediate burst effect and thereafter a sustained release of sufficient ibuprofen to maintain blood levels at least 6.4 μg/ml over an extended period of at least 8 ... 03/23/06 - 20060062850 - Controlled release antimicrobial polymer compositions Antimicrobial polymers that are able to release antimicrobial agents at a controlled rate over a predetermined period of time are provided. The antimicrobial polymers comprise an acid copolymer, an antimicrobial agent, and optionally, an organic acid. The acid copolymer and the organic acid, if present, may be at least partially ... 03/23/06 - 20060062849 - Oral formulation of creatine derivatives and method of manufacturing same Oral formulation of creatine derivative and in particular creatine esters and more particularly ethyl esters of creatine are described. The formulations comprise a phosphate such as dicalcium phosphate, a biodegradable polymer such as a polyvinyl pyrrolidine and a starch. The formulation may further comprise other excipients such as metal salt ... 03/16/06 - 20060057197 - Pharmaceutical dosage forms having immediate release and/or controlled release properties The present invention relates generally to pharmaceutical dosage forms comprising: an absorption window active agent; a controlled release component comprising enteric-coated controlled release beads, wherein the enteric-coated release beads comprise at least two pH-sensitive polymer layers. The controlled-release dosage forms provide good bioavailability of absorption window active agents. ... 03/09/06 - 20060051418 - Pharmaceutical formulations of potassium atp channel openers and uses thereof Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel ... 03/09/06 - 20060051417 - Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix, the matrix comprising at least two water swelling polymers, wherein one of the polymers is pregelatinized starch, and wherein another one of the polymers is an anionic polymer. ... 03/09/06 - 20060051416 - Modified release formulations of memantine oral dosage forms The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active ... 03/02/06 - 20060045912 - 4-phenylbutyric acid controlled-release formulations for therapeutic use Controlled-release formulations and dosage forms containing 4-phenylbutyric acid sodium salt, or other pharmaceutically acceptable salts, esters or prodrugs, and a controlled release material for use in the treatment of diseases and disorders including neoplastic disorders and neurodegenerative diseases The formulations provide extended release and extended half-life. ... 02/23/06 - 20060039975 - Paroxetine formulations Paroxetine is a drug used to treat psychiatric problems such as depression. Controlled release dosage forms comprising release-retarding materials other than hydroxypropyl methylcellulose are described. Also described are methods of wet granulating controlled release paroxetine dosage forms. ... 02/23/06 - 20060039974 - Sustained release preparation The sustained-release preparation of the present invention, which contains a dipeptidyl peptidase IV inhibitor and a hydrophilic polymer, can appropriately inhibit the DPP-IV activity, and is superior in convenience or compliance. ... 02/16/06 - 20060034926 - Controlled release system The invention relates to a system for controlled release of medicinally active substances, which comprises sucrose acetate isobutyrate (SAIB) and a further solvent. ... 02/16/06 - 20060034925 - Tumor targeting drug-loaded particles A composition for delivering a tumor therapeutic agent to a patient includes a fast-release formulation of a tumor apoptosis inducing agent, a slow-release formulation of a tumor therapeutic agent, and a pharmaceutically acceptable carrier. An apoptosis-inducing agent in a pharmaceutically acceptable carrier may be administered before or concomitantly therewith. Nanoparticles ... 02/16/06 - 20060034924 - Mesostructured silica/block copolymer monoliths as a controlled release device and methods of manufacture The invention comprises the design, synthesis, and characterization of mesostructured silica/block copolymer composite monoliths as controlled release systems. The controlled release function is based on the formation of mesostructured silica/block copolymer architectures via surfactant-templated sol-gel processing. Multi-layered or gradient monoliths are produced by layer-by-layer sol-gel processing to provide pulsed and ... 02/16/06 - 20060034923 - Pharmaceutical compositions for controlled release delivery of biologically active compounds The present invention provides compositions and methods for the controlled release delivery of one or more biologically active compounds to a subject. Specifically, the invention provides for a pharmaceutical composition for the controlled release delivery of biologically active compounds to a subject comprising: a) a complex of a biologically active ... 02/16/06 - 20060034922 - Controlled release metformin compositions A method for treating a patient using an antidiabetic drug, said method comprising administering to the patient a high dose of the antidiabetic drug wherein said antidiabetic drug exhibits one or more dose proportional pharmacokinetic parameters is described. ... 02/09/06 - 20060029669 - Antidiabetic preparation for oral administration There is provided a single preparation which directly decreases both of the post prandial blood glucose level and the fasting blood glucose level close to normal levels, by release-sustaining a drug capable of decreasing the post prandial blood glucose level of diabetic patients close to the normal level, or mixing ... 02/09/06 - 20060029668 - Sustained release l-arginine formulations and methods of manufacture and use The present invention provides methods and formulations for the treatment and prevention of cerebrovascular and cardiovascular diseases and disorders. The present invention is based, at least in part, on the discovery that administering to a subject a formulation comprising an agonist of endothelial nitric oxide synthase (eNOS), such as an ... 02/02/06 - 20060024367 - Controlled release alpha lipoic acid formulation with an inositol compound A biphasic formulation of an inositol compound and lipoic acid for oral administration is disclosed. The lipoic acid and the inositol compound are combined with excipient materials in such a way that those materials provide for an immediate release of a first portion of the active ingredients from the formulation ... 02/02/06 - 20060024366 - Modified release compositions of milnacipran A once-a-day oral milnacipran modified release formulation has been developed. The formulation comprises an extended release dosage unit (optionally containing the immediate release portion) coated with delayed release coating. The milnacipran composition, when administered orally, first passes through the stomach releasing from zero to less than 10% of the total ... 02/02/06 - 20060024365 - Novel dosage form A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ... 01/26/06 - 20060018964 - Pharmaceutical formulation and process for its preparation The present invention relates to a multiparticulate tablet with improved gastro-protection comprising at least a pharmaceutically active substance in the form of enteric coated particles, and a mixture of tableting excipients, wherein the said mixture of excipients comprising xylitol and/or maltitol, each in a directly compressible form, a disintegrating agent, ... 01/26/06 - 20060018963 - Extended release venlafaxine besylate tablets Venlafaxine besylate is formulated into an extended release tablet in high loading rates by use of a coating that contains ammonio methacrylate copolymer(s). ... 01/26/06 - 20060018962 - Sustained release formulation of tramadol This invention relates to sustained release oral dosage forms comprising tramadol or a salt thereof dispersed in a matrix, wherein said matrix comprises xanthan gum. ... 01/19/06 - 20060013875 - Combination immediate release controlled release levodopa/carbidopa dosage forms The present invention relates to pharmaceutical dosage forms of a combination of carbidopa and levodopa comprising both immediate release and controlled release components for the treatment of ailments associated with depleted amounts of dopamine in a patient's brain tissue, which dosage forms display no food effect or at least substantially ... 01/19/06 - 20060013874 - Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1-benzopyran-2-one The present invention relates to an extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one or a pharmaceutically acceptable salt thereof or a hydrate of said pharmaceutically acceptable salt thereof. The invention further relates to the preparation of these extended release formulations and their use in the prevention or treatment of disorders, especially pain ... 01/12/06 - 20060008526 - Controlled release metformin compositions A composition for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at 5.5 ... 01/12/06 - 20060008525 - Controlled release metformin compositions A composition for treating patients having non-insulin-dependent diabetes mellitus (NIDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at 5.5 ... 01/12/06 - 20060008524 - Controlled release metformin compositions A composition for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at 5.5 ... 01/12/06 - 20060008523 - Controlled release metformin compositions A composition for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at 5.5 ... 01/05/06 - 20060003004 - Pulsatile release compositions of milnacipran A once-a-day oral milnacipran pulsatile release composition has been developed that releases the drug in spaced apart “pulses”. The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. This dosage form provides in vivo drug plasma levels ... 01/05/06 - 20060003003 - Oral sustained release formulation of tedisamil with gastric retention properties The present invention relates to a novel sustained release formulation with gastric retention properties comprising tedisamil or a pharmaceutically acceptable salt thereof and the use of this formulation in the prevention and treatment of atrial fibrillation, atrial flutter and cardiac ischemia. ... 01/05/06 - 20060003002 - Pharmaceutical compositions with synchronized solubilizer release Pharmaceutical compositions with synchronized solubilizer release as well as various methods associated therewith, are disclosed and described. More specifically, the aqueous solubility of a drug is enhanced by synchronized release of a solubilizer. ... 01/05/06 - 20060003001 - Chronotherapeutic compositions and methods of their use b) a Tmax at about 8 to about 12 hours; c) a drug plasma level within 50% of the peak for greater than or equal to 12 hours; and d) a peak-to-trough ratio of drug plasma levels greater than or equal to about 4. ... 12/29/05 - 20050287210 - Sustained release l-arginine formulations and methods of manufacture and use The present invention provides methods and formulations for the treatment and prevention of cerebrovascular and cardiovascular diseases and disorders. The present invention is based, at least in part, on the discovery that administering to a subject a formulation comprising an agonist of endothelial nitric oxide synthase (eNOS), such as an ... 12/22/05 - 20050281873 - Universal controlled-release composition The present invention relates to a controlled-release pharmaceutical composition comprising at least one active agent and an inactive matrix, said matrix comprising chitosan and derivatives thereof, and further comprising a hydrophilic polysaccharide polymer selected from the group of carbohydrate gums, specifically xanthan gum, and to the preparation and use of ... 12/15/05 - 20050276852 - Sustained release formulations of guaifenesin and additional drug ingredients The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin and at least one additional drug ingredient. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), ... 12/15/05 - 20050276851 - Sustained release aminopyridine composition A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of ... 12/15/05 - 20050276850 - Controlled release sodium valproate formulation Disclosed is a controlled release formulation comprising valproic acid, pharmaceutically acceptable salt thereof, amide thereof, or derivative thereof. ... 12/15/05 - 20050276849 - Sustained release dosage forms The present invention is directed to sustained release neutralized divalproex sodium oral dosage forms, processes for preparing the same, and methods of treatment therewith. ... 12/15/05 - 20050276848 - Sustained release neutralized divalproex sodium The present invention is directed to sustained release oral dosage forms comprising neutralized divalproex sodium, methods of manufacturing the dosage forms, and methods of treatment with the dosage forms. ... 12/08/05 - 20050271723 - Dosage forms for treatment of benign prostatic hyperplasia A method for treatment or prophylaxis of benign prostatic hyperplasia by administration of lonidarrine or a lonidamine analog is provided. Also provided are unit dosage forms of lonidamine or an analog, useful for such treatment and prophylaxis. ... 12/08/05 - 20050271722 - Sustained release formulations The present invention relates broadly to the field of sustained release formulations. More specifically, the invention describes compositions and methods relating to formulating proteins and/or peptides with purified gallic acid esters. In one example, the gallic acid ester is PentaGalloylGlucose (PGG) and in anther example the gallic acid ester is ... 12/01/05 - 20050266076 - Resorbable delivery systems for the treatment of cancer This invention relates generally to the production and use of inorganic-polymer complexes for the controlled release of anti-cancer agents. Advantageously, the inorganic used is calcium sulfate. The invention also includes novel methods of treating cancer. ... 11/24/05 - 20050260266 - Controlled release oral delivery systems Oral delivery systems including at least one encapsulated active are provided. The oral delivery systems include at least one active component; and a polymer matrix at least partially encapsulating the at least one active component. In some embodiments, the polymer matrix has a tensile strength of at least about 6,500 ... 11/24/05 - 20050260265 - Mesostructured silica/block copolymer monoliths as a controlled release device and methods of manufacture The invention comprises the design, synthesis, and characterization of mesostructured silica/block copolymer composite monoliths as controlled release systems. The controlled release function is based on the formation of mesostructured silica/block copolymer architectures via surfactant-templated sol-gel processing. Multi-layered or gradient monoliths are produced by layer-by-layer sol-gel processing to provide pulsed and ... 11/24/05 - 20050260264 - Dosage form for delivery of multiple drug forms Disclosed are controlled release dosage forms and related methods including: (a) a micronized or liquid base form of a drug; (b) either a pharmaceutically acceptable salt form of the drug or starting materials that are capable of reacting to form a pharmaceutically acceptable salt form of the drug; (c) an ... 11/24/05 - 20050260263 - Sustained release formulation for sparingly soluble main drugs A sustained release, solid pharmaceutical preparation for oral use in a daily dosage regimen is provided, which comprises at least one sparingly soluble main drug, such as an erythromycin derivative. The pharmaceutical preparation comprises the main drug(s), a water-soluble alginate salt and an organic carboxylic acid. In particular, a controlled ... 11/17/05 - 20050255157 - Sustained release, mucoadhesive vaginal pharmaceutical compositions A sustained release, mucoadhesive vaginal pharmaceutical composition is provided comprising (a) an effective amount of at least one active pharmaceutical ingredient and (b) a hydrophilic matrix having mucoadhesive properties and capable of providing a sustained release of the active pharmaceutical ingredient, the hydrophilic matrix comprising a hydrophilic polymer having a ... 11/10/05 - 20050249809 - Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative and a disintegrating agent is herein disclosed and described. The dosage formulation exhibits a significant increase in bioavailability of the thiazolidinedione derivative component compared to conventional immediate ... 11/03/05 - 20050244496 - Controlled-release sedative-hypnotic compositions and methods related thereto Controlled-release formulations providing a “pulsed” plasma profile of a sedative-hypnotic compounds having a particularly short half-life are provided. The formulation contains a sedative-hypnotic compound or precursor thereof that is metabolized to generate a sedative-hypnotic compound in vivo, wherein the compound has a mean plasma half life ranging from 0.1 to ... 11/03/05 - 20050244495 - Tranexamic acid formulations Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith. ... 11/03/05 - 20050244494 - Controlled releases system containing temozolomide The present invention relates to a controlled release system, in particular to a controlled release system containing temozolomide. ... 10/27/05 - 20050238715 - Developing a delivery system for multi-pharmaceutical active materials at various release rates The invention provides a novel pharmaceutical compositions useful for the delivery of more than one pharmaceutically active compound. More specifically, the invention provides a novel pharmaceutical compositions useful for the delivery of the (+) tramadol enantiomer and the (−) tramadol enantiomer. ... 10/27/05 - 20050238714 - Anti-fungal composition An anti-fungal product for delivering at least two different anti-fungals that is comprised of three dosage forms with different release profiles with each anti-fungal being present in at least one of the dosage forms. ... 10/20/05 - 20050232993 - Dosage form containing promethazine and another drug A pharmaceutical dosage form which comprises promethazine and/or a pharmaceutically acceptable salt thereof and at least one second drug. The dosage form provides a plasma concentration within the therapeutic range of the at least one second drug over a period which is coextensive with a substantial part of the period ... 10/20/05 - 20050232992 - Proton pump inhibitor formulations, and methods of preparing and using such formulations Pharmaceutical formulation comprising at least one proton pump inhibitor structured and arranged to provide an initial pH independent time-based delayed-release, and a subsequent extended-release of the at least one proton pump inhibitor. ... 10/13/05 - 20050226927 - Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a gabab receptor agonist The present invention relates generally to pharmaceutical dosage forms having immediate release and controlled release properties that contain a γ-aminobutyric acid (GABAB) receptor agonist, e.g., baclofen, for the treatment of medical conditions, which includes spasms, cramping, and tightness of muscles, associated with ailments such as multiple sclerosis or certain spinal ... 10/13/05 - 20050226926 - Sustained-release tablet composition of pramipexole A sustained-release pharmaceutical composition in a form of an orally deliverable tablet comprises a water-soluble salt of pramipexole, dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cm−2 at a solid fraction representative of the tablet. ... 10/06/05 - 20050220875 - Sustained-release tablet formulation The invention provides a sustained-release tablet that can release caffeine and other xanthine derived stimulants at a nearly constant rate. The tablet comprises a hydrophilic polymer of high molecular weight and in one embodiment, the tablet includes caffeine and poly(ethylene oxide) of molecular weight of about 4×106 to 8×106. Sustained ... 10/06/05 - 20050220874 - Pharmaceutical dosage forms having immediate release and controlled release properties that contain a gabab receptor agonist The present invention relates generally to pharmaceutical dosage forms having immediate release and controlled release properties that contain a γ-aminobutyric acid (GABAB) receptor agonist, e.g., baclofen, for the treatment of medical conditions, which includes spasms, cramping, and tightness of muscles, associated with ailments such as multiple sclerosis or certain spinal ... 10/06/05 - 20050220873 - Pharmaceutical dosage forms having immediate and controlled release properties that contain a gabab receptor agonist The present invention relates generally to pharmaceutical dosage forms having immediate release and controlled release properties that contain a γ-aminobutyric acid (GABAB) receptor agonist, e.g., baclofen, for the treatment of medical conditions, which includes spasms, cramping, and tightness of muscles, associated with ailments such as multiple sclerosis or certain spinal |